Hamburg Center for Health Economics, Universität Hamburg, Esplanade 36, 20354 Hamburg, Germany; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
Health Policy. 2013 Oct;112(3):187-96. doi: 10.1016/j.healthpol.2013.04.011. Epub 2013 May 10.
The aim of this study was to analyze influences of process- and technology-related characteristics on the outcomes of coverage decisions. Using survey data on 77 decisions from 13 countries, we examined whether outcomes differ by 14 variables that describe components of decision-making processes and the technology. We analyzed the likelihood of committees covering a technology, i.e. positive (including partial coverage) vs. negative coverage decisions. We performed non-parametric univariate tests and binomial logistic regression with a stepwise variable selection procedure. We identified a negative association between a positive decision and whether the technology is a prescribed medicine (p=0.0097). Other significant influences on a positive decision outcome included one disease area (p=0.0311) and whether a technology was judged to be (cost-)effective (p<0.0001). The first estimation of the logistic regression yielded a quasi-complete separation for technologies that were clearly judged (cost-)effective. In uncertain decisions, a higher number of stakeholders involved in voting (odds ratio=2.52; p=0.03) increased the likelihood of a positive outcome. The results suggest that decisions followed the lines of evidence-based decision-making. Despite claims for transparent and participative decision-making, the phase of evidence generation seemed most critical as decision-makers usually adopted the assessment recommendations. We identified little impact of process configurations.
本研究旨在分析与流程和技术相关的特征对覆盖决策结果的影响。我们使用来自 13 个国家的 77 项决策的调查数据,检验了 14 个描述决策过程和技术组成部分的变量是否会导致结果产生差异。我们分析了委员会是否涵盖某项技术,即是否做出积极(包括部分覆盖)或否定的覆盖决策。我们进行了非参数单变量检验和二项逻辑回归,并采用逐步变量选择程序。我们发现,积极决策与该技术是否为规定药物之间呈负相关(p=0.0097)。对积极决策结果有其他显著影响的因素包括一个疾病领域(p=0.0311)和技术是否被判断为具有(成本)效益(p<0.0001)。逻辑回归的第一次估计对数表明,对于那些被明确判断为(成本)有效的技术,存在准完全分离的情况。在不确定的决策中,参与投票的利益相关者人数较多(优势比=2.52;p=0.03),增加了积极结果的可能性。结果表明,决策符合循证决策的原则。尽管人们声称决策过程是透明和参与性的,但证据生成阶段似乎最为关键,因为决策者通常会采纳评估建议。我们发现流程配置的影响很小。